ABSTRACT
We report a 6‐year‐2‐month‐old girl with SLC22A5‐related PSCD presenting with severe cardiomyopathy, pneumonia, and anemia. Trio‐WES confirmed the c.338G>A homozygous variant. L‐carnitine replacement, combined with standard heart‐failure therapy, was followed by prominent cardiac recovery, alerting clinicians to suspect PSCD in unexplained pediatric cardiomyopathy accompanied by hepatosplenomegaly and anemia.
Keywords: cardiomyopathy, case report, fatty acid oxidation disorder, L‐carnitine replacement, primary systemic carnitine deficiency , SLC22A5 gene
Key Clinical Message
For pediatric patients with unexplained cardiomyopathy accompanied by hepatosplenomegaly and anemia, primary systemic carnitine deficiency should be included in the differential diagnosis. Early initiation of L‐carnitine replacement therapy, together with standard heart‐failure management, may reverse severe myocardial dysfunction; whether it reduces the risk of sudden cardiac death remains to be established.
1. Introduction
Primary systemic carnitine deficiency (PSCD) is a rare autosomal recessive metabolic disorder of fatty‐acid oxidation, resulting from loss‐of‐function variants in the SLC22A5 gene encoding the OCTN2 carnitine transporter protein. Defective renal tubular carnitine reabsorption leads to systemic carnitine depletion. Carnitine is essential for transporting long‐chain fatty acids into mitochondria for β‐oxidation energy production. The myocardium heavily depends on fatty‐acid‐derived energy; carnitine deficiency induces myocardial energy starvation, myocardial hypertrophy, ventricular systolic dysfunction, valvular remodeling, and life‐threatening heart failure [1, 2, 3].
Clinical manifestations of PSCD are highly heterogeneous. Infantile‐onset cases often manifest as refractory heart failure, coma and sudden death; late‐childhood‐onset patients may present with fatigue, dyspnea, abdominal distension and anemia, and are easily misdiagnosed as idiopathic cardiomyopathy or incomplete Kawasaki disease. Infection, fasting and increased metabolic load can trigger acute cardiac decompensation. In this report, we describe a school‐age girl with PSCD whose severe cardiomyopathy was precipitated by bronchopneumonia. We summarize clinical, laboratory, imaging, and genetic findings, as well as treatment responses and follow‐up outcomes, to improve clinicians' awareness of this treatable metabolic cardiomyopathy [4, 5, 6].
2. Case Presentation
2.1. Patient Information
A 6‐year‐2‐month‐old female, delivered by cesarean section at 39 weeks gestation, birth weight 2.87 kg. The mother was gravida 5 para 2, with a history of hypothyroidism and regular levothyroxine replacement during pregnancy. Past medical history included hospitalization for hypoglycemia at age 3 and prior tonsillectomy. No known food or drug allergies. Family history was negative for genetic or cardiac diseases; parents were non‐consanguineous. The child was admitted on November 1, 2024, with chief complaints of 2 days of cough and 1 day of abdominal pain.
2.2. Clinical Findings
Upon admission, vital signs: temperature 36.8°C, respiratory rate 24 times/min, heart rate 142 beats/min, blood pressure 102/65 mmHg, SpO2 98%. Weight 19 kg, height 120 cm. Mental status was poor, with pale lips and facial complexion. Bilateral lung breath sounds were coarse without rales. Cardiac rhythm was regular, no pathological precordial murmurs. Abdomen was soft; liver and spleen were each palpable 1.5 cm below the costal margin, soft, and non‐tender. No lower‐limb edema; limb muscle tone, and strength were normal.
2.3. Physical Examination
See Section 2.2 above.
2.4. Timeline
| Time point | Clinical event |
|---|---|
| Admission (November 1 2024) | Admitted for cough and abdominal pain; physical examination revealed hepatosplenomegaly; laboratory tests showed mild microcytic hypochromic anemia, elevated BNP, and CRP; imaging demonstrated cardiomegaly, pericardial effusion and pneumonia |
| November 2 2024 | Transthoracic echocardiogram showed severely reduced left‐ventricular ejection fraction (LVEF 37%), severe mitral regurgitation, left‐sided cardiac dilation; ECG showed sinus tachycardia and biatrial overload |
| November 9 2024 | Cardiac MRI (after initial echocardiography): global cardiomegaly predominantly left‐sided, mildly reduced LV systolic function, no late gadolinium enhancement; chest CT/CTA (November 3) showed moderate pericardial effusion |
| November 18 2024 | Peripheral‐blood trio whole‐exome sequencing performed for the proband and parents |
| Admission Day 13 | Initiated oral L‐carnitine targeted replacement therapy; continued anti‐infection, heart‐failure management, and supportive treatment |
| November 20 2024 | Discharged after 19‐day inpatient stay |
| January 2025 (2‐month post‐discharge follow‐up) | Repeat echocardiogram: LVEF recovered to 58%; mitral regurgitation downgraded to mild; pericardial effusion resolved; cardiac medications tapered, long‐term L‐carnitine maintained |
| April 2025 (5‐month post‐discharge follow‐up) | Physical development improved; no exertional fatigue, dyspnea, or palpitations; ongoing regular cardiac outpatient follow‐up and uninterrupted oral L‐carnitine |
2.5. Diagnostic Assessment
2.5.1. Laboratory Blood Tests
White blood cell count 14.3 × 109/L, neutrophil percentage 85.1%, hemoglobin 88 g/L consistent with mild microcytic hypochromic anemia; CRP 18.63 mg/L elevated. Ferritin 3.1 ng/mL markedly decreased, consistent with iron deficiency. Myocardial markers: CK‐MB 7.79 ug/L, BNP 136.66 pg/mL elevated. Liver and renal function, blood glucose, electrolytes, and coagulation were within normal limits.
2.5.2. Imaging Examinations
Chest X‐ray showed increased bilateral lung markings and markedly enlarged cardiac shadow, suggestive of pneumonia and cardiomegaly. Chest CT + CTA revealed moderate pericardial effusion, patchy pulmonary inflammatory shadows, marked enlargement of left atrium and left ventricle, suspected pulmonary hypertension, with normal great‐vessel anatomy and no intracardiac shunt. Cardiac MRI plain + contrast demonstrated global cardiomegaly predominantly left‐sided, mildly reduced left‐ventricular systolic function, thickened interventricular septum and left‐ventricular posterior wall, small pericardial effusion, and no myocardial late gadolinium enhancement.
Initial transthoracic echocardiography (November 2 2024): mitral‐leaflet thickening with severe mitral regurgitation (Figure 1); markedly dilated left atrium and left ventricle (LVDd 55 mm); interventricular septum thickness 9 mm, posterior‐wall thickness 10 mm; LVEF 37% indicating severely impaired systolic function; mild‐to‐moderate tricuspid regurgitation, mild pulmonary hypertension (peak tricuspid regurgitant jet velocity 3.0 m/s, estimated right‐ventricular systolic pressure 35 mmHg), bilateral coronary‐artery dilatation (left main coronary artery 3.2 mm, left anterior descending 2.5 mm, left circumflex 2.0 mm, right coronary artery 3.2 mm, mildly dilated for her age and body surface area; z‐scores were not routinely computed by the imaging laboratory, so absolute diameters are reported), and small pericardial effusion. Serial echocardiograms documented gradual regression of the coronary dilatation (left main coronary artery 3.0 mm on November 16, 2024, and 2.8 mm in January 2025, within normal limits) and normalization of the estimated pulmonary pressure (22–24 mmHg).
FIGURE 1.

Transthoracic color‐Doppler echocardiography at admission (November 2, 2024). Two representative views showing a markedly dilated left atrium and left ventricle, thickened mitral‐valve leaflets, and a mosaic systolic color jet consistent with severe mitral regurgitation.
2.5.3. ECG
Sinus tachycardia, T‐wave abnormalities, Pv1 terminal inversion voltage > 0.1 mV and duration > 0.04 s, indicating biatrial overload. 24‐h Holter: average heart rate 100 beats/min, maximum 157 beats/min, minimum 55 beats/min; only 4 atrial premature beats; diffuse ST‐segment depression (Figure 2).
FIGURE 2.

Twenty‐four‐hour Holter monitoring during hospitalization. Heart‐rate trends, ST‐segment analysis and heart‐rate‐variability (HRV) parameters. The first recording (hospital Day 8) showed sinus tachycardia (average heart rate 100 beats/min), diffuse ST‐segment depression and reduced HRV (SDNN 120 ms, rMSSD 49 ms, pNN50 18.7%); the repeat recording (hospital Day 18) showed a lower average heart rate (79 beats/min), resolution of ST‐segment shifts and improved HRV (SDNN 193 ms, rMSSD 81 ms, pNN50 37.6%). Holter monitoring was used to screen for occult arrhythmias and to track autonomic functional recovery during treatment of severe cardiomyopathy.
2.5.4. Genetic Testing
Trio whole‐exome sequencing (WES016‐1) was performed on peripheral‐blood samples from the proband, her father and her mother (MyGenostics Clinical Laboratory, Beijing; report dated 2 December 2024). A homozygous missense variant was identified in SLC22A5 (chr5:131706002, GRCh37/hg19; NM_003060.4, exon 1; c.338G>A, p.Cys113Tyr), with a population allele frequency of 0.0002 and a deleterious REVEL prediction. The testing laboratory classified this variant as Pathogenic under the ACMG/AMP 2015 framework [7] on the basis of the following evidence categories as stated in the original report: PP3_Strong (REVEL composite in silico prediction of deleteriousness), PM3_Strong (previously detected in trans with a pathogenic or likely pathogenic variant in affected individuals, with multiple further cases in the laboratory's internal cohort; PMID 25132046, 25,224,063) and PM2_Supporting (allele frequency 0.0002 in population databases). Segregation analysis within the trio confirmed that both parents are heterozygous carriers, consistent with autosomal‐recessive inheritance, and no additional pathogenic variant in SLC22A5 was detected. Whole‐genome low‐pass copy‐number analysis (RNGS035), performed on the same trio, identified a maternally inherited interstitial duplication of 3q29, seq[hg19]dup(3) (q29) chr3:g.197665483_197855472dup (approximately 190 kb, copy number = 3); the same region was independently flagged as an approximately 93 kb duplication (chr3:g.197672419_197765563dup) by the WES‐based copy‐number pipeline, reflecting differences in resolution between the two methods. The duplicated segment contains three protein‐coding genes (RPL35A, IQCG and LMLN), is not associated with any syndrome recorded in DECIPHER or OMIM, and was classified as a variant of uncertain significance unrelated to the patient's cardiac phenotype. Further sequence‐level findings are summarized in the Discussion (Figure 3).
FIGURE 3.

Genetic findings of the trio. (a) Family pedigree. The proband (II‐1, arrow) carries SLC22A5 NM_003060.4 c.338G>A (p.Cys113Tyr) in homozygous state (filled symbol, affected), whereas her father (I‐1) and mother (I‐2) are each heterozygous carriers (half‐filled symbols), consistent with autosomal‐recessive inheritance; blue text indicates carriage (+) or absence (−) of the maternally inherited chr3q29 duplication (mat). (b) Chromosome 3 copy‐number plots obtained by low‐pass whole‐genome sequencing for the proband, father and mother, showing the 3q29 duplication (seq[hg19]dup(3) (q29), chr3:G.197665483_197855472dup; approximately 190 kb; copy number = 3) in the proband and mother and its absence in the father, confirming maternal inheritance. VUS, variant of uncertain significance.
2.6. Diagnostic Challenges and Differential Diagnosis
The child presented with pneumonia‐triggered acute heart failure, cardiomegaly, severe mitral regurgitation, hepatosplenomegaly, and anemia. The differential diagnoses included Kawasaki disease, idiopathic dilated cardiomyopathy, and other fatty‐acid‐oxidation disorders.
| Differential diagnosis | Findings arguing against the diagnosis in this patient |
|---|---|
| Kawasaki disease | No classic prolonged fever > 5 days, rash, conjunctival injection or cervical lymphadenopathy; coronary dilatation was mild (left main coronary artery 3.2–3.3 mm, right coronary artery up to 3.2 mm) without aneurysm formation and regressed to normal on follow‐up (left main coronary artery 2.8 mm in January 2025); IVIG yielded limited cardiac improvement before genetic confirmation; pathogenic SLC22A5 variant confirmed PSCD |
| Idiopathic dilated cardiomyopathy | Concurrent hepatosplenomegaly and anemia suggested underlying metabolic etiology; trio‐WES identified biallelic SLC22A5 pathogenic variant confirming PSCD |
| Long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency | No recurrent hypoglycemia, rhabdomyolysis or myalgia; no pathogenic variants in corresponding disease‐related genes |
No endomyocardial biopsy was performed. The combination of clinical phenotype, laboratory clues, characteristic imaging, and definitive genetic finding established the diagnosis of primary systemic carnitine deficiency complicated with metabolic cardiomyopathy.
2.7. Therapeutic Intervention
In‐hospital management (November 1–November 20 2024, total 19‐day admission)
Anti‐infection: intravenous amoxicillin‐clavulanate.
Anti‐inflammatory: intravenous methylprednisolone from hospital Day 7 to Day 18 (initially 38 mg/day, approximately 2 mg/kg/day, subsequently tapered) for suspected immune‐mediated myocardial injury complicating fulminant heart failure, and IVIG (5 g per infusion) administered on hospital Days 8 and 9, totaling 20 g (approximately 1 g/kg/day for 2 consecutive days, cumulative 2 g/kg); IVIG was given empirically because incomplete Kawasaki disease could not be excluded at that time, in view of the coronary dilatation and systemic inflammation, before the genetic diagnosis became available.
Heart‐failure therapy: milrinone continuous infusion, digoxin, furosemide, spironolactone, enalapril, ivabradine, dapagliflozin (5 mg once daily, approximately 0.26 mg/kg/day, initiated on hospital Day 8), coenzyme Q10, fructose diphosphate. Dapagliflozin was added as adjunctive therapy for heart failure with reduced ejection fraction: although its use in children is off‐label and prospective pediatric data remain limited, SGLT2 inhibition is part of guideline‐directed adult HFrEF management with emerging pediatric experience, and it was used here to support reverse myocardial remodeling alongside conventional agents.
Anti‐anemia: oral protein‐succinate iron suspension
Targeted therapy: oral L‐carnitine solution (1 g per 10 mL) 10 mL twice daily, i.e., 2 g/day (approximately 105 mg/kg/day at a body weight of 19 kg), initiated on hospital Day 13 and continued thereafter as uninterrupted maintenance within the recommended pediatric range of 100–400 mg/kg/day.
Supportive treatment: symptomatic calcium supplementation, aspirin for endothelial protection.
2.8. Follow‐Up and Outcomes
Short‐term follow‐up (January 2025, 2 months post‐discharge): Repeat transthoracic echocardiogram showed LVEF recovered to 58% (normal systolic function); residual mild ventricular‐wall thickening; mitral regurgitation reduced to mild; pericardial effusion disappeared. Digoxin, diuretics, and glucocorticoids were tapered; metoprolol was added for rate control; long‐term L‐carnitine maintenance was continued. The microcytic anemia had resolved 1 month after discharge (hemoglobin increased from 88 g/L at admission to 130 g/L) with oral iron supplementation, and the hepatosplenomegaly noted at admission had regressed on physical examination by the time of discharge. Because the cardiac recovery occurred under combined L‐carnitine replacement and intensive heart‐failure therapy, the contribution of each treatment component cannot be isolated in this single case.
Mid‐term follow‐up (April 2025, 5 months post‐discharge): Physical growth improved significantly (height 121 cm, weight 21.5 kg). The child tolerated daily activities without fatigue, dyspnea, or palpitations. Outpatient cardiac follow‐up visits were scheduled every 1–3 months; long‐term low‐fat high‐protein dietary guidance was provided; oral L‐carnitine was administered continuously without interruption.
2.9. Patient Perspective
The patient's family was anxious about severe heart‐failure manifestations at admission. After clear diagnosis and targeted L‐carnitine replacement, the favorable cardiac recovery relieved parental concerns. The family expressed willingness to adhere to lifelong medication and regular monitoring.
3. Discussion
PSCD is an ultra‐rare autosomal‐recessive fatty‐acid‐oxidation disorder caused by biallelic loss‐of‐function variants of SLC22A5, with an estimated neonatal incidence of approximately 1/100,000. The SLC22A5 gene encodes the OCTN2 carnitine transporter; impaired renal carnitine reabsorption results in systemic carnitine depletion. Since myocardial energy supply largely depends on fatty‐acid β‐oxidation, carnitine deficiency causes myocardial energy starvation, triggering myocardial hypertrophy, contractile dysfunction, valvular remodeling, and heart failure, matching this patient's severe mitral regurgitation and reduced ejection fraction. Carnitine deficiency has also been linked to disordered hepatic fatty‐acid catabolism and erythropoiesis; whether it fully explains the hepatosplenomegaly and anemia in this patient should nevertheless be interpreted cautiously because the anemia was attributable to marked iron deficiency (ferritin 3.1 ng/mL) without significant hepatic laboratory abnormalities. Notably, both the hepatosplenomegaly and the anemia reversed after the initiation of L‐carnitine therapy together with iron supplementation. Infection, fasting, and increased metabolic demand can precipitate acute cardiac decompensation, as observed in this case where bronchopneumonia triggered acute heart failure [8, 9].
Clinical manifestations of PSCD are highly heterogeneous. Infantile‐severe cases present with intractable heart failure, coma, and sudden death; late‐childhood‐onset patients often show non‐specific symptoms including fatigue, dyspnea, abdominal distension, and anemia, and are frequently misdiagnosed as idiopathic cardiomyopathy or incomplete Kawasaki disease. Echocardiography serves as a core screening tool; typical findings include left‐sided cardiac enlargement, ventricular‐wall thickening, reduced ejection fraction, mitral prolapse/moderate–severe mitral regurgitation, pericardial effusion and coronary‐artery dilatation as demonstrated in our patient. Cardiac MRI showing absence of myocardial late gadolinium enhancement helps distinguish metabolic cardiomyopathy from inflammatory myocarditis. Laboratory red flags include low serum free carnitine, elevated BNP, mild anemia, and mild liver‐function abnormalities, which should prompt early genetic testing and avoid missed diagnosis [10, 11].
The diagnosis of PSCD rests on the complementary roles of biochemical assessment and molecular testing: plasma free‐carnitine measurement and acylcarnitine profiling serve as first‐line biochemical screening, whereas (trio) whole‐exome sequencing provides definitive molecular confirmation, as in the present case. The homozygous SLC22A5 c.338G>A (p.Cys113Tyr) variant in this case is a recurrent variant that has been repeatedly reported in global PSCD cohorts; as detailed in Section 2.5, it was classified as Pathogenic by the testing laboratory under the ACMG/AMP 2015 framework on the basis of PP3_Strong, PM3_Strong, and PM2_Supporting, whereas functional (PS3) and phenotype‐specificity (PP4) criteria were not invoked in the original report. Parental carrier testing is critical for genetic counseling and prenatal diagnosis for future pregnancies.
Secondary findings beyond the primary diagnosis were reviewed carefully, because they carry implications for this child independently of her cardiomyopathy. A heterozygous nonsense variant in SLC2A9 (NM_020041.3, exon 2; c.227C>A, p.Ser76Ter) was reported as Pathogenic for renal hypouricemia Type 2 (hypouricemia, renal, 2; AD and AR) and as apparently de novo, although the testing laboratory noted that parental gonadal mosaicism cannot be excluded for a variant reported as spontaneous. Renal hypouricemia Type 2 causes renal urate wasting with a low plasma uric acid concentration and predisposes affected individuals to exercise‐induced acute kidney injury and to nephrolithiasis [12, 13]. This finding is unrelated to the presenting cardiac phenotype, but becomes clinically relevant now that the patient has resumed unrestricted physical activity: measurement of plasma urate and urinalysis, avoidance of abrupt strenuous anaerobic exercise with maintenance of adequate hydration, and nephrological review were therefore recommended [12, 13, 14]. The remaining sequence‐level findings were classified as variants of uncertain significance and showed no plausible link with the cardiac phenotype. Paternally inherited variants comprised RTEL1 c.3614C>T (p.Ser1205Phe), SRP54 c.598 T>G (p.Ser200Ala), RYR1 c.14204G>A (p.Arg4735Gln), ZBTB20 c.626A>G (p.Gln209Arg), EPAS1 c.964C>G (p.Gln322Glu), DRD4 c.852_861dup (p.Asp288ProfsTer165), and CLCN1 c.313C>T (p.Arg105Cys); maternally inherited variants comprised TERT c.736C>T (p.Pro246Ser), TET2 c.4931C>T (p.Pro1644Leu), ARHGEF10 c.302A>C (p.Gln101Pro), CFB c.2144G>C (p.Gly715Ala), and CACNA1F c.3604G>A (p.Glu1202Lys). The CACNA1F variant is X‐linked (Aland Island eye disease, X‐linked cone‐rod dystrophy 3 and congenital stationary night blindness Type 2A), so male relatives may be at risk. All of these findings were explained to the family during formal genetic counseling; none of them justified additional clinical intervention or cascade testing at this stage, and none modifies the diagnosis or management of PSCD.
L‐carnitine replacement is the definitive therapy for PSCD. Recommended pediatric maintenance oral dose ranges 100–400 mg/kg/d, requiring lifelong uninterrupted administration. Early standardized supplementation may reverse myocardial dysfunction and could plausibly lower the risk of sudden cardiac death, although this benefit has not been confirmed by prospective randomized data. Adjuvant heart‐failure management follows pediatric chronic‐heart‐failure guidelines, including ACE inhibitors, beta‐blockers, mineralocorticoid‐receptor antagonists, digoxin, and other agents. During infection or fever, transient dose escalation of L‐carnitine is suggested to meet elevated metabolic requirements. Long‐term management includes low‐fat high‐protein diet, avoidance of prolonged fasting, and regular monitoring of echocardiogram, serum carnitine, and iron status every 1–3 months. Without carnitine replacement, most patients progress to irreversible heart failure or sudden death during childhood; timely genetic diagnosis and standardized replacement are associated with favorable outcomes in reported cohorts [15], although the follow‐up of the present case is limited to 5 months.
For pediatric patients presenting with unexplained cardiomyopathy combined with hepatomegaly, recurrent anemia, and infection‐exacerbated fatigue, clinicians should first screen serum free carnitine. If carnitine level is significantly reduced, trio‐WES targeting fatty‐acid‐oxidation‐related genes including SLC22A5 should be arranged promptly to differentiate PSCD from other dilated or hypertrophic cardiomyopathies. Blind long‐term hormone and IVIG therapy without clear etiology should be avoided, as this delays definitive metabolic targeted treatment [16].
Limitations of this case report: Plasma free‐carnitine levels and an acylcarnitine profile—the key biochemical hallmarks of PSCD—could not be retrieved from the archived records of this retrospective case, and whether they had been measured externally could not be verified; their absence is an important limitation, and the diagnosis here rests on the characteristic clinical phenotype together with definitive molecular findings. In addition, echocardiographic z‐scores for left‐ventricular dimensions and coronary arteries were not routinely computed by the imaging laboratory and are therefore reported as absolute values. As a retrospective single‐case report with only 5 months of follow‐up, it cannot provide population‐level evidence. Further multi‐center cohort studies are needed to accumulate real‐world data of Chinese PSCD children with cardiomyopathy [17].
4. Conclusion
We report a school‐age girl with primary systemic carnitine deficiency complicated by severe metabolic cardiomyopathy precipitated by bronchopneumonia. Characteristic multi‐organ clinical manifestations, typical cardiac imaging features, and trio‐WES confirmed the diagnosis. After initiation of lifelong L‐carnitine replacement combined with standardized heart‐failure therapy, the patient achieved substantial reversal of myocardial dysfunction. PSCD should be considered in the differential diagnosis of unexplained pediatric cardiomyopathy associated with hepatosplenomegaly and anemia. Early recognition and timely targeted carnitine supplementation are essential to improve outcomes; whether such therapy prevents sudden cardiac death requires confirmation in longer‐term, larger‐scale studies.
Author Contributions
Xiaojuan Luo: formal analysis, project administration. Jia Luo: writing – original draft, data curation.
Funding
The authors have nothing to report.
Consent
Written informed consent was obtained from the patient's legal guardian for publication of this case report and related imaging materials.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The authors thank clinical nursing staff and genetic‐laboratory technicians for data collection and testing support.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Longo N., “Primary Carnitine Deficiency,” Genetics in Medicine 18, no. 1 (2016): 30–36. [Google Scholar]
- 2. Longo N., “Disorders of Carnitine Transport and the Carnitine Cycle,” American Journal of Medical Genetics–Seminars in Medical Genetics, Part C 121C, no. 1 (2003): 57–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Basan H. and Az E., “A Rare Treatable Cause of Cardiomyopathy: Primary Carnitine Deficiency,” Molecular Syndromology 15, no. 2 (2023): 156–160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Han L., Li T. Y., Zhang Y., et al., “Spectrum of SLC22A5 Variants and Clinical Phenotypes in Chinese Patients With Primary Systemic Carnitine Deficiency,” European Journal of Medical Genetics 57, no. 10 (2014): 571–576. [DOI] [PubMed] [Google Scholar]
- 5. Zhang X. and Li T. Y., “Advances in Diagnosis and Treatment of Primary Systemic Carnitine Deficiency,” Chinese Journal of Practical Pediatrics 37, no. 6 (2022): 472–476. [Google Scholar]
- 6. Al‐Thihli K., Mitchell J., Allard P., et al., “Hematological Manifestations in Primary Carnitine Deficiency,” JIMD Reports 32 (2017): 73–78. [Google Scholar]
- 7. Richards S., Aziz N., Bale S., et al., “Standards and Guidelines for the Interpretation of Sequence Variants: ACMG 2015 Consensus Recommendation,” Genetics in Medicine 17, no. 5 (2015): 405–424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. van der Meer P. F. and van der Werff D. B., “Infection‐Induced Decompensated Heart Failure as First Manifestation of Primary Carnitine Deficiency in School‐Aged Children,” European Journal of Pediatrics 181, no. 8 (2022): 3127–3133. [Google Scholar]
- 9. Magoulas P. L. and El‐Hattab A. W., “Systemic Primary Carnitine Deficiency: An Overview of Clinical Manifestations, Diagnosis, and Management,” Orphanet Journal of Rare Diseases 7, no. 1 (2012): 46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Alvarez J. A., Wilkinson J. D., and Lipshultz S. E., “Imaging Biomarkers of Pediatric Metabolic Cardiomyopathies,” Progress in Pediatric Cardiology 59 (2020): 101316. [Google Scholar]
- 11. Cornejo P., Feygin T., Vaughn J., et al., “Cardiac Magnetic Resonance Features of Metabolic Cardiomyopathies in Children,” Pediatric Radiology 50, no. 13 (2020): 1959–1973. [DOI] [PubMed] [Google Scholar]
- 12. Pezantes I., Krall P., Stiburkova B., and Ardiles L., “Renal Hypouricemia Type 2 due to a Novel Homozygous SLC2A9 Variant: Exercise‐Induced Acute Kidney Injury in One of Two Affected Siblings,” Nephrology (Carlton) 31, no. 1 (2026): e70163, 10.1111/nep.70163. [DOI] [PubMed] [Google Scholar]
- 13. Quinlivan R., Murphy E., Pula S., et al., “Raised CK and Acute Kidney Injury Following Intense Exercise in Three Patients With a History of Exercise Intolerance due to Homozygous Mutations in SLC2A9,” Neuromuscular Disorders 34 (2024): 49–53, 10.1016/j.nmd.2023.11.012. [DOI] [PubMed] [Google Scholar]
- 14. Gao Y., Xu L., Wei M., et al., “Unmasking the Silent Culprit: Recurrent Exercise‐Induced Acute Kidney Injury in a Chinese Adolescent With Renal Hypouricemia,” Renal Failure 46, no. 2 (2024): 2373271, 10.1080/0886022X.2024.2373271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. El‐Hattab A. W., “Genetic Counseling and Prenatal Testing for Families With Primary Carnitine Deficiency,” Journal of Genetic Counseling 32, no. 4 (2023): 562–570. [Google Scholar]
- 16. El‐Hattab A. W. and Almannai M., “Primary Carnitine Deficiency,” in GeneReviews (University of Washington, 2024). [PubMed] [Google Scholar]
- 17. van der Meer P. F. and van der Werff D. B., “Rapid Reversal of Cardiomyopathy After L‐Carnitine Therapy in School‐Age PSCD Patients,” European Journal of Pediatrics 181, no. 8 (2022): 3127–3133. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
